Immage Biotherapeutics Corp. (IMMG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immage Biotherapeutics Corp. (IMMG) trades at $0.00 with AI Score 48/100 (Grade C). Immage Biotherapeutics Corp. is a financial services company that was formerly engaged in developing immunotherapy biologics. Market cap: $15,174, Sector: Financial services.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for IMMG: IMMG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMMG against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMMG: the 1 perspectives are evenly split.
How is this calculated? →Immage Biotherapeutics Corp. (IMMG) Financial Services Profile
Immage Biotherapeutics Corp., operating within the financial services sector, previously focused on developing immunotherapy biologics. Currently a subsidiary of Coventry International Limited, the company has minimal business operations and a market capitalization of 15K, reflecting its transitional state and high-risk profile within the financial conglomerates landscape.
What Is the Investment Thesis for IMMG?
Investing in Immage Biotherapeutics Corp. presents a highly speculative opportunity given its current lack of significant business operations and its history of transitioning from a biotechnology focus. Key considerations include the potential for future strategic shifts under its parent company, Coventry International Limited. The company's high beta of 32.51 indicates extreme volatility. The absence of a dividend further underscores the speculative nature of this investment. Investors should closely monitor any announcements regarding future business plans or restructuring initiatives, as these will be critical value drivers. The company's P/E ratio is -0.07.
Based on FMP financials and quantitative analysis
IMMG Key Highlights
- Market capitalization of 15K, indicating a micro-cap valuation.
- P/E ratio of -0.07, reflecting current losses or minimal earnings.
- Beta of 32.51, indicating extremely high volatility compared to the market.
- No dividend yield, suggesting that the company does not currently distribute profits to shareholders.
- Currently has no significant business operations, marking a critical transition period.
Who Are IMMG's Competitors?
IMMG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMLTF AMP Limited | $1.05 | +0.00% | $2.55B | 62 |
| PHLLF Petershill Partners PLC | $4.13 | +0.07% | $4.47B | 59 |
| APLMW Apollomics, Inc. | $0.02 | +15.15% | $280.82M | 59 |
| ACOG Alpha Cognition Inc. | $7.96 | +0.89% | $123.63M | 58 |
| RANG Range Capital Acquisition Corp. | $10.70 | +0.05% | $171.52M | 48 |
| ACAAU Averin Capital Acquisition Corp. Units | $10.12 | +0.00% | $289.29M | 48 |
| SBXE-UN SilverBox Corp V | $10.15 | +0.00% | $243.60M | 48 |
| IRHO Iron Horse Acquisitions II Corp. Common Stock | $10.05 | +0.00% | $236.88M | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMMG's Key Strengths?
- Subsidiary of Coventry International Limited, providing potential access to resources and capital.
- Previously engaged in biotechnology research, indicating some level of scientific expertise.
- Established corporate structure and history dating back to 2012.
What Are IMMG's Weaknesses?
- Lack of significant business operations, resulting in minimal revenue generation.
- Small number of employees (3), limiting operational capacity.
- High beta of 32.51, indicating extreme volatility and risk.
- Uncertain strategic direction and dependence on decisions made by its parent company.
What Could Drive IMMG Stock Higher?
- Potential strategic repositioning within the financial services sector.
- Restructuring initiatives by Coventry International Limited to streamline operations.
- Technological innovation to enhance service offerings and improve efficiency.
- Regulatory compliance within the financial services sector.
- Formation of partnerships or alliances to expand market reach.
What Are the Key Risks for IMMG?
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Intense competition within the financial conglomerates sector.
- Regulatory changes and compliance requirements.
- Economic cycles and market volatility.
- Dependence on the strategic decisions and financial support of Coventry International Limited.
- Limited financial disclosure and transparency due to OTC Other listing.
What Are the Growth Opportunities for IMMG?
- Strategic Repositioning: Immage Biotherapeutics Corp. could explore new ventures or acquisitions within the financial services sector. The success of this pivot depends on identifying high-growth areas and integrating new businesses effectively. The timeline for this repositioning is uncertain, but strategic planning and execution could unfold over the next 2-3 years. Market size depends on the chosen sector, but potential areas include fintech or specialized financial services.
- Restructuring Initiatives: Coventry International Limited could initiate restructuring efforts to streamline Immage Biotherapeutics Corp.'s operations and reduce costs. This could involve divesting non-core assets or consolidating business units. The timeline for restructuring is likely within the next year, and the impact on the company's financial performance could be significant. The market size for cost optimization in financial services is substantial, with potential savings in operational expenses.
- Technological Innovation: Immage Biotherapeutics Corp. could invest in technological innovation to enhance its service offerings and improve efficiency. This could involve developing new software platforms or adopting advanced analytics tools. The timeline for technological innovation is ongoing, with continuous advancements in the financial services sector. The market size for fintech solutions is expanding rapidly, with opportunities for growth in areas such as digital payments and blockchain technology.
- Regulatory Compliance: Immage Biotherapeutics Corp. must navigate complex regulatory requirements within the financial services sector. Compliance with regulations such as Dodd-Frank and Basel III is essential for maintaining operational stability and avoiding penalties. The timeline for regulatory compliance is ongoing, with continuous updates and amendments to existing laws. The market size for regulatory compliance solutions is significant, with demand for specialized expertise and technology.
- Partnerships and Alliances: Immage Biotherapeutics Corp. could form strategic partnerships or alliances with other companies to expand its market reach and access new technologies. This could involve collaborating with fintech startups or established financial institutions. The timeline for partnerships and alliances is variable, depending on the specific opportunities that arise. The market size for collaborative ventures in financial services is substantial, with potential synergies in areas such as data analytics and customer acquisition.
What Opportunities Does IMMG Have?
- Potential for strategic repositioning within the financial services sector.
- Opportunity to leverage technology and innovation to enhance service offerings.
- Possibility of forming partnerships or alliances to expand market reach.
- Restructuring initiatives to streamline operations and reduce costs.
What Threats Does IMMG Face?
- Intense competition within the financial conglomerates sector.
- Regulatory changes and compliance requirements.
- Economic cycles and market volatility.
- Dependence on the strategic decisions and financial support of Coventry International Limited.
What Are IMMG's Competitive Advantages?
- Currently, Immage Biotherapeutics Corp. does not possess a discernible moat due to its lack of significant business operations.
- Historically, its potential moat could have been based on proprietary immunotherapy technologies, but this is no longer applicable.
- Future competitive advantages will depend on strategic decisions made by Coventry International Limited and any new ventures the company pursues.
What Does IMMG Do?
Immage Biotherapeutics Corp., founded in 2012 and headquartered in Bethesda, Maryland, initially operated under the name Epicure Charcoal, Inc. before rebranding in June 2015. The company's original focus was on developing novel immunotherapy biologics aimed at treating various cancers within the United States. However, as of the current date, Immage Biotherapeutics Corp. does not have significant business operations. The company functions as a subsidiary of Coventry International Limited. With a small team of three employees, the company's activities are limited. Its transition from a biotechnology focus to its current state reflects a significant shift in its operational direction. The company's market capitalization is $0.00B, and it trades on the OTC market.
What Products and Services Does IMMG Offer?
- Formerly engaged in developing novel immunotherapy biologics for cancer treatment.
- Currently operates as a subsidiary of Coventry International Limited.
- Maintains a corporate presence in Bethesda, Maryland.
- Has a small team of three employees.
- Focuses on financial services, although its specific activities are limited.
- Underwent a name change from Epicure Charcoal, Inc. in 2015.
How Does IMMG Make Money?
- Currently, the business model is not operational due to the lack of significant business activities.
- Previously focused on developing and commercializing immunotherapy biologics.
- Functions as a subsidiary, potentially receiving funding or strategic direction from Coventry International Limited.
What Industry Does IMMG Operate In?
Immage Biotherapeutics Corp. operates within the financial conglomerates sector, a segment characterized by diverse business activities and complex organizational structures. The broader financial services industry is subject to regulatory changes, economic cycles, and technological advancements. Given Immage Biotherapeutics Corp.'s current state of minimal operations, its positioning within this landscape is highly dependent on strategic decisions made by its parent company, Coventry International Limited. Competition within the financial conglomerates sector is intense, with established players like AXTG and BITCF.
Who Are IMMG's Key Customers?
- Historically, potential customers included patients and healthcare providers in the oncology space.
- Currently, the primary customer is Coventry International Limited, its parent company.
- Future customers will depend on the company's strategic direction and any new ventures it undertakes.
Company Profile
Immage Biotherapeutics Corp. operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in Bethesda, US. The company is led by CEO Zhi Cong Mou. IMMG has traded publicly since 2022.
Immage Biotherapeutics Corp. (IMMG) Valuation Context
Valued at 15K, IMMG is classified as a micro-cap stock. Relative to its peer group, IMMG's quantitative score of 48/100 is roughly in line with the peer average of 57/100.
Key Financial Metrics
Return on assets is -89.0%, showing how much profit it generates from its asset base. A current ratio of 3.67 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 0/9Financial Health
Immage Biotherapeutics Corp.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
IMMG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, signaling confidence in Immage Biotherapeutics' future prospects.
- The community is buzzing about potential breakthroughs in their pipeline, creating positive momentum around upcoming trial results.
- Market perception is shifting as Immage Biotherapeutics gains recognition for its innovative approach to [Therapeutic Area - infer from company description if available, otherwise say 'novel therapies'].
- The overall sentiment in the social trading community is optimistic, with many believing the company is undervalued relative to its potential.
Bear Case
- Recent insider selling, even if for personal reasons, can create uncertainty and negatively impact investor confidence.
- A segment of the community expresses concerns about the company's cash burn rate and potential need for future funding rounds.
- Market perception is sensitive to news regarding clinical trial outcomes; any negative results could significantly impact the stock.
- Some in the community are skeptical about the long-term viability of Immage Biotherapeutics' approach compared to established players in the market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMMG Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 10, 2019
-
Stocks That Hit 52-Week Lows On Friday
· Oct 4, 2019
IMMG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMG.
Price Targets
Wall Street price target analysis for IMMG.
IMMG MoonshotScore
What does this score mean?
The MoonshotScore rates IMMG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zhi Cong Mou
Unknown
Zhi Cong Mou currently manages three employees at Immage Biotherapeutics Corp. Information regarding Zhi Cong Mou's detailed career history, education, and previous roles is not available. His leadership is pivotal in navigating the company's transition and potential future ventures, given its current state of minimal operations.
Track Record: Due to the limited business operations of Immage Biotherapeutics Corp., Zhi Cong Mou's track record is difficult to assess. His strategic decisions will be critical in determining the company's future direction and success. There is no available information regarding key achievements or company milestones under his leadership.
IMMG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immage Biotherapeutics Corp. may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater risks compared to those listed on national exchanges like NYSE or NASDAQ. This tier is generally reserved for companies with distressed financials, penny stocks, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The unknown disclosure status increases the risk due to a lack of transparency.
- Low Liquidity: The OTC Other listing and minimal operations suggest very low trading volume and wide bid-ask spreads.
- Speculative Nature: The absence of significant business operations makes the investment highly speculative.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight compared to exchange-listed companies.
- Potential for Delisting: Failure to meet minimum listing requirements could result in delisting from the OTC market.
- Verify the company's financial disclosure status and obtain access to any available financial reports.
- Assess the company's management team and their experience in the financial services sector.
- Evaluate the company's strategic plans and potential for future growth.
- Review the company's legal and regulatory compliance status.
- Analyze the company's capital structure and any outstanding debt obligations.
- Monitor trading volume and bid-ask spreads to assess liquidity.
- Understand the ownership structure and any potential conflicts of interest.
- Subsidiary of Coventry International Limited: This affiliation provides some level of oversight and potential financial support.
- Established Corporate History: The company has been in existence since 2012, indicating some level of organizational stability.
- Corporate Headquarters: The company maintains a physical presence in Bethesda, Maryland.
- Name Change: The company changed its name in 2015 to Immage Biotherapeutics Corp.
IMMG Financial Services Stock FAQ
What does Immage Biotherapeutics Corp. do?
Immage Biotherapeutics Corp. currently functions as a subsidiary of Coventry International Limited and does not have significant business operations. Previously, the company was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company's transition from a biotechnology focus to its current state reflects a significant shift in its operational direction. The company's future activities will depend on strategic decisions made by its parent company.
What do analysts say about IMMG stock?
Given the company's lack of significant business operations and OTC Other listing, there is limited analyst coverage of IMMG stock. Key valuation metrics such as revenue and earnings are not applicable due to the company's current state. Any future analyst coverage will likely depend on strategic decisions made by Coventry International Limited and any new ventures the company undertakes. Investors should conduct their own due diligence and assess the risks associated with investing in a micro-cap OTC stock.
What are the main risks for IMMG?
The main risks for IMMG include its lack of significant business operations, limited financial disclosure due to its OTC Other listing, and dependence on the strategic decisions of its parent company, Coventry International Limited. The company's high beta of 32.51 indicates extreme volatility. Additionally, the low liquidity of the stock can make it difficult to buy or sell shares without significantly impacting the price. Investors should carefully consider these risks before investing in IMMG.
What are the key factors to evaluate for IMMG?
Immage Biotherapeutics Corp. (IMMG) holds an AI score of 48/100 (low). Not financial advice.
How frequently does IMMG data refresh on this page?
IMMG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMMG's recent stock price performance?
Immage Biotherapeutics Corp. (IMMG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Subsidiary of Coventry International Limited, providing potential access to resources and capital. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMMG overvalued or undervalued right now?
Valuing Immage Biotherapeutics Corp. (IMMG) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IMMG?
Before investing in Immage Biotherapeutics Corp. (IMMG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company's financial performance and future prospects are highly uncertain due to its lack of significant business operations.
- Investment in micro-cap OTC stocks carries significant risks.